Easy to use delivery technology could prevent opioid overdose deaths
The National Institute on Drug Abuse (NIDA) is pleased to announce that Adapt Pharma Limited, a partner of Lightlake Therapeutics Inc., has commenced a rolling submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for a nasal spray formulation of naloxone, a drug designed to prevent opioid overdose deaths. A rolling submission allows completed portions of the NDA to be submitted and reviewed by the FDA on an ongoing basis.
NIDA and Lightlake Therapeutics Inc., a biopharmaceutical company developing novel treatments for addiction, entered into a partnership in 2013 to apply new technology towards development of a potentially lifesaving intervention for opioid overdose.
Naloxone can rapidly reverse opioid overdose. The only current FDA approved method of administering naloxone is by injection. An FDA-approved intranasal delivery system could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the U.S.
For more information, contact the NIDA press office at firstname.lastname@example.org or 301-443-6245.